Aclaris醫療 ACRS 深 滬
等待開盤 12-10 09:30:00 美东时间
3.21
-0.070
-2.13%
華盛通- 最 高3.325
- 今 開3.30
- 成交量 138.56万股
- 最 低 3.19
- 昨 收 3.28
- 總市值 3.47亿
- 52周最高 3.35
- 市盈率 靜 --
- 換手率 1.28%
- 52周最低 1.05
- 委 比 -42.72%
- 總股本 1.08亿
- 歷史最高 33.88
- 量 比 1.05
- 振 幅 4.12%
- 歷史最低 0.5902
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aclaris Therapeutics announced that its CEO, Dr. Neal Walker, and other senior leaders will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, at 11:00 AM EST. A live and archived webcast will be available on the company's website for at least 30 days. Aclaris specializes in developing novel treatments for immuno-inflammatory diseases. For more information, visit www.aclaris...
11-25 13:00
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 9.09 percent decrease over losses of $(0.11) per share
11-06 20:24
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics reported positive results from its Phase 2a trial of ITK/JAK3 inhibitor ATI-2138 in atopic dermatitis, validating ITK as a therapeutic target. The company expects to initiate a Phase 2 trial for an additional indication in 2026 and file an IND for a next-generation ITK inhibitor in 2026. Aclaris also provided updates on its biologics pipeline, including Phase 1b proof-of-concept trials for ATI-052 in asthma and AD, and plans ...
11-06 11:59
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
10-20 19:39
Aclaris Therapeutics To Host 2025 R&D Day In Midtown, New York On October 14 To Discuss Its Progress In Addressing Therapeutic Gaps In Immuno-Inflammatory Markets
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it's 2025
09-30 19:14
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Aclaris Therapeutics is hosting its 2025 R&D Day on October 14, 2025, in New York. The event will feature presentations by company leadership, Dr. Zuzana Diamant, and Dr. Michael C. Cameron, discussing Aclaris' progress in developing novel treatments for immune-inflammatory diseases. Topics include its innovative discovery platform, ITK inhibition franchise, TSLP franchise, and clinical trial updates. A live Q&A session and webcast will be availa...
09-30 11:00
An Overview of High Tide's Earnings
High Tide (NASDAQ:HITI) is preparing to release its quarterly earnings on Monda...
09-12 22:00
Aclaris Therapeutics' ATI-2138 Phase 2a Trial Results To Be Presented At 2025 EADV Congress In Paris For Moderate-To-Severe Atopic Dermatitis
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis-WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage
09-09 19:20
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aclaris Therapeutics, Inc. announced that a late-breaking abstract on its Phase 2a trial of ATI-2138, an investigational oral inhibitor of ITK and JAK3, was selected for presentation at the 2025 EADV Congress in Paris. The presentation will include additional results from the Phase 2a trial in patients with moderate-to-severe atopic dermatitis. ATI-2138, which targets T cell function and IL-2ϒc signaling, has shown potential in preclinical models...
09-09 11:00
